Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer

Blood first assay screening in patients with ALK positive NSCLC

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial

Breast cancer highlights from ESMO 2019

Melanoma highlights from ESMO 2019

IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer